|
1
|
Murad AM, Santiago FF, Petroianu A, Rocha
PR, Rodrigues MA and Rausch M: Modified therapy with
5-fluorouracil, doxorubicin, and methotrexate in advanced gastric
cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pyrhönen S, Kuitunen T, Nyandoto P and
Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and
methotrexate (FEMTX) plus supportive care with supportive care
alone in patients with non-resectable gastric cancer. Br J Cancer.
71:587–591. 1995.PubMed/NCBI
|
|
3
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohtsu A, Shimada Y, Shirao K, et al:
Randomized phase III trial of fluorouracil alone versus
fluorouracil plus cisplatin versus uracil and tegafur plus
mitomycin in patients with unresectable, advanced gastric cancer:
The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol.
21:54–59. 2003. View Article : Google Scholar
|
|
5
|
Vanhoefer U, Rougier P, Wilke H, et al:
Final results of a randomized phase III trial of sequential
high-dose methotrexate, fluorouracil, and doxorubicin versus
etoposide, leucovorin, and fluorouracil versus infusional
fluorouracil and cisplatin in advanced gastric cancer: A trial of
the European Organization for Research and Treatment of Cancer
Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol.
18:2648–2657. 2000.
|
|
6
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al: Phase III study of docetaxel and cisplatin plus fluorouracil
compared with cisplatin and fluorouracil as first-line therapy for
advanced gastric cancer: a report of the V325 Study Group. J Clin
Oncol. 24:4991–4997. 2006.PubMed/NCBI
|
|
7
|
Cunningham D, Starling N, Rao S, et al:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rougier P, van Cutsem E, Bajetta E, et al:
Randomised trial of irinotecan versus fluorouracil by continuous
infusion after fluorouracil failure in patients with metastatic
colorectal cancer. Lancet. 352:1407–1412. 1998. View Article : Google Scholar
|
|
10
|
Cunningham D, Pyrhönen S, James RD, et al:
Randomised trial of irinotecan plus supportive care versus
supportive care alone after fluorouracil failure for patients with
metastatic colorectal cancer. Lancet. 352:1413–1418. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Futatsuki K, Wakui A, Nakao I, et al: Late
phase II study of irinotecan hydrochloride (CPT-11) in advanced
gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To
Kagaku Ryoho. 21:1033–1038. 1994.PubMed/NCBI
|
|
12
|
Kanat O, Evrensel T, Manavoglu O, et al:
Single-agent irinotecan as second-line treatment for advanced
gastric cancer. Tumori. 89:405–407. 2003.PubMed/NCBI
|
|
13
|
Boku N, Ohtsu A, Shimada Y, et al: Phase
II study of a combination of irinotecan and cisplatin against
metastatic gastric cancer. J Clin Oncol. 17:319–323.
1999.PubMed/NCBI
|
|
14
|
Im CK, Rha SY, Jeung HC, et al: A phase II
study of a combined biweekly irinotecan and monthly cisplatin
treatment for metastatic or recurrent gastric cancer. Am J Clin
Oncol. 33:56–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ajani JA, Baker J, Pisters PW, et al:
Irinotecan/cisplatin in advanced, treated gastric or
gastroesophageal junction carcinoma. Oncology. 16:16–18.
2002.PubMed/NCBI
|
|
16
|
Boku N, Yamamoto S, Fukuda H, et al:
Fluorouracil versus combination of irinotecan plus cisplatin versus
S-1 in metastatic gastric cancer: a randomised phase 3 study.
Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ajani JA, Rodriguez W, Bodoky G, et al:
Multicenter phase III comparison of cisplatin/S-1 with
cisplatin/infusional fluorouracil in advanced gastric or
gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin
Oncol. 28:1547–1553. 2010. View Article : Google Scholar
|
|
18
|
Thuss-Patience PC, Kretzschmar A, Deist T,
et al: Irinotecan versus best supportive care (BSC) as second-line
therapy in gastric cancer. A randomized phase III study of the
Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol.
27(Suppl 15): 45402009.
|
|
19
|
Nagashima F, Boku N, Ohtsu A, et al:
Biological markers as a predictor for response and prognosis of
unresectable gastric cancer patients treated with irinotecan and
cisplatin. Jpn J Clin Oncol. 35:714–719. 2005. View Article : Google Scholar : PubMed/NCBI
|
